2vgb: Difference between revisions

No edit summary
No edit summary
Line 4: Line 4:


==Overview==
==Overview==
Deficiency of human erythrocyte isozyme (RPK) is, together with, glucose-6-phosphate dehydrogenase deficiency, the most common cause of the, nonspherocytic hemolytic anemia. To provide a molecular framework to the, disease, we have solved the 2.7 A resolution crystal structure of human, RPK in complex with fructose 1,6-bisphosphate, the allosteric activator, and phosphoglycolate, a substrate analogue, and we have functionally and, structurally characterized eight mutants (G332S, G364D, T384M, D390N, R479H, R486W, R504L, and R532W) found in RPK-deficient patients. The, mutations target distinct regions of RPK structure, including domain, interfaces and catalytic and allosteric sites. The mutations affect to a, different extent thermostability, catalytic efficiency, and regulatory, properties. These studies are the first to correlate the clinical symptoms, with the molecular properties of the mutant enzymes. Mutations greatly, impairing thermostability and/or activity are associated with severe, anemia. Some mutant proteins exhibit moderate changes in the kinetic, parameters, which are sufficient to cause mild to severe anemia, underlining the crucial role of RPK for erythrocyte metabolism. Prediction, of the effects of mutations is difficult because there is no relation, between the nature and location of the replaced amino acid and the type of, molecular perturbation. Characterization of mutant proteins may serve as a, valuable tool to assist with diagnosis and genetic counseling.
Deficiency of human erythrocyte isozyme (RPK) is, together with glucose-6-phosphate dehydrogenase deficiency, the most common cause of the nonspherocytic hemolytic anemia. To provide a molecular framework to the disease, we have solved the 2.7 A resolution crystal structure of human RPK in complex with fructose 1,6-bisphosphate, the allosteric activator, and phosphoglycolate, a substrate analogue, and we have functionally and structurally characterized eight mutants (G332S, G364D, T384M, D390N, R479H, R486W, R504L, and R532W) found in RPK-deficient patients. The mutations target distinct regions of RPK structure, including domain interfaces and catalytic and allosteric sites. The mutations affect to a different extent thermostability, catalytic efficiency, and regulatory properties. These studies are the first to correlate the clinical symptoms with the molecular properties of the mutant enzymes. Mutations greatly impairing thermostability and/or activity are associated with severe anemia. Some mutant proteins exhibit moderate changes in the kinetic parameters, which are sufficient to cause mild to severe anemia, underlining the crucial role of RPK for erythrocyte metabolism. Prediction of the effects of mutations is difficult because there is no relation between the nature and location of the replaced amino acid and the type of molecular perturbation. Characterization of mutant proteins may serve as a valuable tool to assist with diagnosis and genetic counseling.


==About this Structure==
==About this Structure==
2VGB is a [http://en.wikipedia.org/wiki/Single_protein Single protein] structure of sequence from [http://en.wikipedia.org/wiki/Homo_sapiens Homo sapiens] with <scene name='pdbligand=FBP:'>FBP</scene>, <scene name='pdbligand=PGA:'>PGA</scene>, <scene name='pdbligand=K:'>K</scene> and <scene name='pdbligand=MN:'>MN</scene> as [http://en.wikipedia.org/wiki/ligands ligands]. This structure superseeds the now removed PDB entry 1LIU. Active as [http://en.wikipedia.org/wiki/Pyruvate_kinase Pyruvate kinase], with EC number [http://www.brenda-enzymes.info/php/result_flat.php4?ecno=2.7.1.40 2.7.1.40] Known structural/functional Sites: <scene name='pdbsite=AC1:Fbp Binding Site For Chain A'>AC1</scene>, <scene name='pdbsite=AC2:Pga Binding Site For Chain A'>AC2</scene>, <scene name='pdbsite=AC3:K Binding Site For Chain A'>AC3</scene>, <scene name='pdbsite=AC4:Mn Binding Site For Chain A'>AC4</scene>, <scene name='pdbsite=AC5:Fbp Binding Site For Chain B'>AC5</scene>, <scene name='pdbsite=AC6:Pga Binding Site For Chain B'>AC6</scene>, <scene name='pdbsite=AC7:K Binding Site For Chain B'>AC7</scene>, <scene name='pdbsite=AC8:Mn Binding Site For Chain B'>AC8</scene>, <scene name='pdbsite=AC9:Fbp Binding Site For Chain C'>AC9</scene>, <scene name='pdbsite=BC1:Pga Binding Site For Chain C'>BC1</scene>, <scene name='pdbsite=BC2:K Binding Site For Chain C'>BC2</scene>, <scene name='pdbsite=BC3:Mn Binding Site For Chain C'>BC3</scene>, <scene name='pdbsite=BC4:Fbp Binding Site For Chain D'>BC4</scene>, <scene name='pdbsite=BC5:Pga Binding Site For Chain D'>BC5</scene>, <scene name='pdbsite=BC6:K Binding Site For Chain D'>BC6</scene> and <scene name='pdbsite=BC7:Mn Binding Site For Chain D'>BC7</scene>. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=2VGB OCA].  
2VGB is a [http://en.wikipedia.org/wiki/Single_protein Single protein] structure of sequence from [http://en.wikipedia.org/wiki/Homo_sapiens Homo sapiens] with <scene name='pdbligand=FBP:'>FBP</scene>, <scene name='pdbligand=PGA:'>PGA</scene>, <scene name='pdbligand=K:'>K</scene> and <scene name='pdbligand=MN:'>MN</scene> as [http://en.wikipedia.org/wiki/ligands ligands]. This structure supersedes the now removed PDB entry 1LIU. Active as [http://en.wikipedia.org/wiki/Pyruvate_kinase Pyruvate kinase], with EC number [http://www.brenda-enzymes.info/php/result_flat.php4?ecno=2.7.1.40 2.7.1.40] Known structural/functional Sites: <scene name='pdbsite=AC1:Fbp+Binding+Site+For+Chain+A'>AC1</scene>, <scene name='pdbsite=AC2:Pga+Binding+Site+For+Chain+A'>AC2</scene>, <scene name='pdbsite=AC3:K+Binding+Site+For+Chain+A'>AC3</scene>, <scene name='pdbsite=AC4:Mn+Binding+Site+For+Chain+A'>AC4</scene>, <scene name='pdbsite=AC5:Fbp+Binding+Site+For+Chain+B'>AC5</scene>, <scene name='pdbsite=AC6:Pga+Binding+Site+For+Chain+B'>AC6</scene>, <scene name='pdbsite=AC7:K+Binding+Site+For+Chain+B'>AC7</scene>, <scene name='pdbsite=AC8:Mn+Binding+Site+For+Chain+B'>AC8</scene>, <scene name='pdbsite=AC9:Fbp+Binding+Site+For+Chain+C'>AC9</scene>, <scene name='pdbsite=BC1:Pga+Binding+Site+For+Chain+C'>BC1</scene>, <scene name='pdbsite=BC2:K+Binding+Site+For+Chain+C'>BC2</scene>, <scene name='pdbsite=BC3:Mn+Binding+Site+For+Chain+C'>BC3</scene>, <scene name='pdbsite=BC4:Fbp+Binding+Site+For+Chain+D'>BC4</scene>, <scene name='pdbsite=BC5:Pga+Binding+Site+For+Chain+D'>BC5</scene>, <scene name='pdbsite=BC6:K+Binding+Site+For+Chain+D'>BC6</scene> and <scene name='pdbsite=BC7:Mn+Binding+Site+For+Chain+D'>BC7</scene>. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=2VGB OCA].  


==Reference==
==Reference==
Line 14: Line 14:
[[Category: Pyruvate kinase]]
[[Category: Pyruvate kinase]]
[[Category: Single protein]]
[[Category: Single protein]]
[[Category: Abraham, D.J.]]
[[Category: Abraham, D J.]]
[[Category: Bianchi, P.]]
[[Category: Bianchi, P.]]
[[Category: Chiarelli, L.]]
[[Category: Chiarelli, L.]]
Line 40: Line 40:
[[Category: transferase]]
[[Category: transferase]]


''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on Wed Jan 23 12:11:12 2008''
''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on Thu Feb 21 18:55:42 2008''

Proteopedia Page Contributors and Editors (what is this?)Proteopedia Page Contributors and Editors (what is this?)

OCA